-
1
-
-
0024358369
-
A rating scale for drug-induced akathisia
-
Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154(5):672-676.
-
(1989)
Br. J. Psychiatry
, vol.154
, Issue.5
, pp. 672-676
-
-
Barnes, T.R.1
-
2
-
-
80055087317
-
Aripiprazole versus placebo for schizophrenia
-
Belgamwar R.B., El-Sayeh H.G. Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst. Rev. 2011, 8:CD006622. 10.1002/14651858.CD14006622.pub14651852.
-
(2011)
Cochrane Database Syst. Rev.
, vol.8
, pp. CD006622
-
-
Belgamwar, R.B.1
El-Sayeh, H.G.2
-
3
-
-
34247542475
-
Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia
-
Brecher M., Leong R.W., Stening G., Osterling-Koskinen L., Jones A.M. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J. Clin. Psychiatry 2007, 68(4):597-603.
-
(2007)
J. Clin. Psychiatry
, vol.68
, Issue.4
, pp. 597-603
-
-
Brecher, M.1
Leong, R.W.2
Stening, G.3
Osterling-Koskinen, L.4
Jones, A.M.5
-
4
-
-
0034434675
-
Determinants of quality of life at first presentation with schizophrenia
-
Browne S., Clarke M., Gervin M., Waddington J.L., Larkin C., O'Callaghan E. Determinants of quality of life at first presentation with schizophrenia. Br. J. Psychiatry 2000, 176:173-176.
-
(2000)
Br. J. Psychiatry
, vol.176
, pp. 173-176
-
-
Browne, S.1
Clarke, M.2
Gervin, M.3
Waddington, J.L.4
Larkin, C.5
O'Callaghan, E.6
-
5
-
-
33750614310
-
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine
-
Chrzanowski W.K., Marcus R.N., Torbeyns A., Nyilas M., McQuade R.D. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006, 189(2):259-266.
-
(2006)
Psychopharmacology
, vol.189
, Issue.2
, pp. 259-266
-
-
Chrzanowski, W.K.1
Marcus, R.N.2
Torbeyns, A.3
Nyilas, M.4
McQuade, R.D.5
-
6
-
-
84887097223
-
A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach
-
Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 2013, 27(11):879-911.
-
(2013)
CNS Drugs
, vol.27
, Issue.11
, pp. 879-911
-
-
Citrome, L.1
-
7
-
-
77954166205
-
From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics
-
Correll C.U. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry 2010, 25(Suppl. 2):S12-S21.
-
(2010)
Eur. Psychiatry
, vol.25
, pp. S12-S21
-
-
Correll, C.U.1
-
8
-
-
84937234454
-
Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial
-
Correll C.U., Skuban A., Ouyang J., Hobart M., Pfister S., McQuade R.D., Nyilas M., Carson W.H., Sanchez R., Eriksson H. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry 2015, 172(9):870-880.
-
(2015)
Am. J. Psychiatry
, vol.172
, Issue.9
, pp. 870-880
-
-
Correll, C.U.1
Skuban, A.2
Ouyang, J.3
Hobart, M.4
Pfister, S.5
McQuade, R.D.6
Nyilas, M.7
Carson, W.H.8
Sanchez, R.9
Eriksson, H.10
-
9
-
-
84964734763
-
Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, doubleblind, placebo-controlled studies
-
Correll C.U., et al. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, doubleblind, placebo-controlled studies. Schizophr. Res. 2016, 10.1016/j.schres.2016.04.012.
-
(2016)
Schizophr. Res.
-
-
Correll, C.U.1
-
10
-
-
84856466929
-
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
-
De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2011, 8(2):114-126.
-
(2011)
Nat. Rev. Endocrinol.
, vol.8
, Issue.2
, pp. 114-126
-
-
De Hert, M.1
Detraux, J.2
van Winkel, R.3
Yu, W.4
Correll, C.U.5
-
11
-
-
84865253275
-
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis
-
De Hert M., Yu W., Detraux J., Sweers K., van Winkel R., Correll C.U. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012, 26(9):733-759.
-
(2012)
CNS Drugs
, vol.26
, Issue.9
, pp. 733-759
-
-
De Hert, M.1
Yu, W.2
Detraux, J.3
Sweers, K.4
van Winkel, R.5
Correll, C.U.6
-
12
-
-
0006618558
-
ECDEU assessment manual for psychopharmacology (revised)
-
National Institute of Mental Health, US Department of Health, Education, and Welfare Publication (ADM) 76-338, Rockville, MD, M. Hamilton (Ed.)
-
Guy W. ECDEU assessment manual for psychopharmacology (revised). Hamilton Anxiety Scale 1976, 193-198. National Institute of Mental Health, US Department of Health, Education, and Welfare Publication (ADM) 76-338, Rockville, MD. M. Hamilton (Ed.).
-
(1976)
Hamilton Anxiety Scale
, pp. 193-198
-
-
Guy, W.1
-
13
-
-
84924968394
-
Validity of subjective versus objective quality of life assessment in people with schizophrenia
-
Hayhurst K.P., Massie J.A., Dunn G., Lewis S.W., Drake R.J. Validity of subjective versus objective quality of life assessment in people with schizophrenia. BMC Psychiatry 2014, 14(1):365.
-
(2014)
BMC Psychiatry
, vol.14
, Issue.1
, pp. 365
-
-
Hayhurst, K.P.1
Massie, J.A.2
Dunn, G.3
Lewis, S.W.4
Drake, R.J.5
-
14
-
-
67049162787
-
Akathisia: an updated review focusing on second-generation antipsychotics
-
Kane J.M., Fleischhacker W.W., Hansen L., Perlis R., Pikalov A., Assuncao-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J. Clin. Psychiatry 2009, 70(5):627-643.
-
(2009)
J. Clin. Psychiatry
, vol.70
, Issue.5
, pp. 627-643
-
-
Kane, J.M.1
Fleischhacker, W.W.2
Hansen, L.3
Perlis, R.4
Pikalov, A.5
Assuncao-Talbott, S.6
-
15
-
-
77951165069
-
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials
-
Kane J.M., Barnes T.R., Correll C.U., Sachs G., Buckley P., Eudicone J., McQuade R., Tran Q.V., Pikalov A., Assuncao-Talbott S. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J. Psychopharmacol. 2010, 24(7):1019-1029.
-
(2010)
J. Psychopharmacol.
, vol.24
, Issue.7
, pp. 1019-1029
-
-
Kane, J.M.1
Barnes, T.R.2
Correll, C.U.3
Sachs, G.4
Buckley, P.5
Eudicone, J.6
McQuade, R.7
Tran, Q.V.8
Pikalov, A.9
Assuncao-Talbott, S.10
-
16
-
-
84928640856
-
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
-
Kane J.M., Skuban A., Ouyang J., Hobart M., Pfister S., McQuade R.D., Nyilas M., Carson W.H., Sanchez R., Eriksson H. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr. Res. 2015, 164(1-3):127-135.
-
(2015)
Schizophr. Res.
, vol.164
, Issue.1-3
, pp. 127-135
-
-
Kane, J.M.1
Skuban, A.2
Ouyang, J.3
Hobart, M.4
Pfister, S.5
McQuade, R.D.6
Nyilas, M.7
Carson, W.H.8
Sanchez, R.9
Eriksson, H.10
-
17
-
-
84936931469
-
Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial
-
Kane J.M., Zukin S., Wang Y., Lu K., Ruth A., Nagy K., Laszlovszky I., Durgam S. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J. Clin. Psychopharmacol. 2015, 35(4):367-373.
-
(2015)
J. Clin. Psychopharmacol.
, vol.35
, Issue.4
, pp. 367-373
-
-
Kane, J.M.1
Zukin, S.2
Wang, Y.3
Lu, K.4
Ruth, A.5
Nagy, K.6
Laszlovszky, I.7
Durgam, S.8
-
18
-
-
0034025771
-
Relationship between dopamine d(2) occupancy, clinical response, and side effects: a double-blind pet study of first-episode schizophrenia
-
Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine d(2) occupancy, clinical response, and side effects: a double-blind pet study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157(4):514-520.
-
(2000)
Am. J. Psychiatry
, vol.157
, Issue.4
, pp. 514-520
-
-
Kapur, S.1
Zipursky, R.2
Jones, C.3
Remington, G.4
Houle, S.5
-
19
-
-
77950870279
-
Quetiapine versus other atypical antipsychotics for schizophrenia
-
Komossa K., Rummel-Kluge C., Schmid F., Hunger H., Schwarz S., Srisurapanont M., Kissling W., Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2010, 1:CD006625. 10.1002/14651858.CD006625.pub2.
-
(2010)
Cochrane Database Syst. Rev.
, vol.1
, pp. CD006625
-
-
Komossa, K.1
Rummel-Kluge, C.2
Schmid, F.3
Hunger, H.4
Schwarz, S.5
Srisurapanont, M.6
Kissling, W.7
Leucht, S.8
-
20
-
-
84898057496
-
2a receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis
-
2a receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 2014, 17(5):823-832.
-
(2014)
Int. J. Neuropsychopharmacol.
, vol.17
, Issue.5
, pp. 823-832
-
-
Laoutidis, Z.G.1
Luckhaus, C.2
-
21
-
-
84884161208
-
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
-
Leucht S., Cipriani A., Spineli L., Mavridis D., Örey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lässig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382(9896):951-962.
-
(2013)
Lancet
, vol.382
, Issue.9896
, pp. 951-962
-
-
Leucht, S.1
Cipriani, A.2
Spineli, L.3
Mavridis, D.4
Örey, D.5
Richter, F.6
Samara, M.7
Barbui, C.8
Engel, R.R.9
Geddes, J.R.10
Kissling, W.11
Stapf, M.P.12
Lässig, B.13
Salanti, G.14
Davis, J.M.15
-
22
-
-
84903982078
-
Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator
-
Maeda K., Sugino H., Akazawa H., Amada N., Shimada J., Futamura T., Yamashita H., Ito N., McQuade R.D., Mork A., Pehrson A.L., Hentzer M., Nielsen V., Bundgaard C., Arnt J., Stensbol T.B., Kikuchi T. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther. 2014, 350(3):589-604.
-
(2014)
J. Pharmacol. Exp. Ther.
, vol.350
, Issue.3
, pp. 589-604
-
-
Maeda, K.1
Sugino, H.2
Akazawa, H.3
Amada, N.4
Shimada, J.5
Futamura, T.6
Yamashita, H.7
Ito, N.8
McQuade, R.D.9
Mork, A.10
Pehrson, A.L.11
Hentzer, M.12
Nielsen, V.13
Bundgaard, C.14
Arnt, J.15
Stensbol, T.B.16
Kikuchi, T.17
-
23
-
-
84904981694
-
Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator
-
Maeda K., Lerdrup L., Sugino H., Akazawa H., Amada N., McQuade R.D., Stensbol T.B., Bundgaard C., Arnt J., Kikuchi T. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther. 2014, 350(3):605-614.
-
(2014)
J. Pharmacol. Exp. Ther.
, vol.350
, Issue.3
, pp. 605-614
-
-
Maeda, K.1
Lerdrup, L.2
Sugino, H.3
Akazawa, H.4
Amada, N.5
McQuade, R.D.6
Stensbol, T.B.7
Bundgaard, C.8
Arnt, J.9
Kikuchi, T.10
-
24
-
-
16644402581
-
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study
-
McQuade R.D., Stock E., Marcus R., Jody D., Gharbia N.A., Vanveggel S., Archibald D., Carson W.H. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry 2004, 65(Suppl. 18):47-56.
-
(2004)
J. Clin. Psychiatry
, vol.65
, pp. 47-56
-
-
McQuade, R.D.1
Stock, E.2
Marcus, R.3
Jody, D.4
Gharbia, N.A.5
Vanveggel, S.6
Archibald, D.7
Carson, W.H.8
-
25
-
-
25444533069
-
Atypical antipsychotics: sleep, sedation, and efficacy
-
Miller D.D. Atypical antipsychotics: sleep, sedation, and efficacy. Prim. Care Companion. J. Clin. Psychiatry. 2004, 6(Suppl. 2):3-7.
-
(2004)
Prim. Care Companion. J. Clin. Psychiatry.
, vol.6
, pp. 3-7
-
-
Miller, D.D.1
-
26
-
-
84863393105
-
The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults
-
Posner K., Brown G.K., Stanley B., Brent D.A., Yershova K.V., Oquendo M.A., Currier G.W., Melvin G.A., Greenhill L., Shen S., Mann J.J. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry 2011, 168(12):1266-1277.
-
(2011)
Am. J. Psychiatry
, vol.168
, Issue.12
, pp. 1266-1277
-
-
Posner, K.1
Brown, G.K.2
Stanley, B.3
Brent, D.A.4
Yershova, K.V.5
Oquendo, M.A.6
Currier, G.W.7
Melvin, G.A.8
Greenhill, L.9
Shen, S.10
Mann, J.J.11
-
27
-
-
84555186903
-
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons
-
Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Kissling W., Davis J.M., Leucht S. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr. Bull. 2012, 38(1):167-177.
-
(2012)
Schizophr. Bull.
, vol.38
, Issue.1
, pp. 167-177
-
-
Rummel-Kluge, C.1
Komossa, K.2
Schwarz, S.3
Hunger, H.4
Schmid, F.5
Kissling, W.6
Davis, J.M.7
Leucht, S.8
-
28
-
-
22144432283
-
A systematic review of the prevalence of schizophrenia
-
Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005, 2(5):e141.
-
(2005)
PLoS Med.
, vol.2
, Issue.5
, pp. e141
-
-
Saha, S.1
Chant, D.2
Welham, J.3
McGrath, J.4
-
29
-
-
17844406880
-
Olanzapine increases slow wave sleep and sleep continuity in ssri-resistant depressed patients
-
Sharpley A.L., Attenburrow M.E., Hafizi S., Cowen P.J. Olanzapine increases slow wave sleep and sleep continuity in ssri-resistant depressed patients. J. Clin. Psychiatry 2005, 66(4):450-454.
-
(2005)
J. Clin. Psychiatry
, vol.66
, Issue.4
, pp. 450-454
-
-
Sharpley, A.L.1
Attenburrow, M.E.2
Hafizi, S.3
Cowen, P.J.4
-
31
-
-
68149160037
-
Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making
-
Volavka J., Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert. Opin. Pharmacother. 2009, 10(12):1917-1928.
-
(2009)
Expert. Opin. Pharmacother.
, vol.10
, Issue.12
, pp. 1917-1928
-
-
Volavka, J.1
Citrome, L.2
|